Drugs / KSH01
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05580796 | Oct 2022 → Oct 2025 overdue | neoplasm | TCRx Therapeutics Co.Ltd | Recruiting | No outcome recorded |
| Phase 0 | NCT05539833 | Aug 2022 → Jul 2025 overdue | refractory malignant neoplasm | TCRx Therapeutics Co.Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KSH01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05539833 ↗ |
| Modality | Cell therapy | “autologous TCR-T cells” NCT05580796 ↗ |